A Comparison of Sodium-Glucose Co-Transporter 2 Inhibitor Kidney Outcome Trial Participants with a Real-World Chronic Kidney Disease Primary Care Population.

Anna K ForbesWilliam HintonMichael D FeherWilliam ElsonJosé M Ordóñez-MenaMark JoyXuejuan FanDebasish BanerjeeNicholas I ColeNeil MunroMartin WhyteRebecca J SucklingPauline A Swift Simon de Lusignan

Published in: Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association (2024)

SGLT2 inhibitor kidney outcome trials represent a sub-group of people with CKD at high risk of adverse kidney events. Out study highlights the importance of complementing trials with real-world studies, exploring the effectiveness of SGLT2 inhibitors in the broader population of people with CKD.

Keyphrases

chronic kidney disease
end stage renal disease
primary care
randomized controlled trial
systematic review
clinical trial
study protocol
phase iii
phase ii
open label
adverse drug